TriAgenics

TriAgenics

Growth Stage

Imagine Eliminating Wisdom Teeth Extractions with a Non-Surgical Procedure!

Imagine Eliminating Wisdom Teeth Extractions with a Non-Surgical Procedure!

Overview

Raised to Date: Raised: $1,506,528

Total Commitments ($USD)

Platform

StartEngine

Start Date

06/07/2023

Close Date

10/09/2023

Min. Goal
$15,000
Max. Goal
$4,000,002
Min. Investment

$300

Security Type

Equity - Preferred

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$3.00

Pre-Money Valuation

$33,867,972

Rolling Commitments ($USD)

Status

Active

Reporting Date

09/28/2023

Days Remaining

11

% of Min. Goal

10,044%

% of Max. Goal

38%

Likelihood of Max
unlikely
Avg. Daily Raise

$13,332

# of Investors

311

Momentum
warm.svg
Create a free account today to gain access to KingsCrowd analytics.
Year Founded

2013

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B2C

Margin

High

Capital Intensity

High

Location

REDMOND, Oregon

Business Type

Growth

TriAgenics, with a valuation of $33.87 million, is raising funds on StartEngine. The company has developed a Zero3 Tooth Bud Ablation technology to eliminate the need for wisdom teeth extractions. The Zero3 TBA technology of TriAgenics offers a high-precision and minimally invasive procedure that prevents the formation of wisdom teeth, thereby eliminating the need for extractions and the associated costs, pain, and recovery time. TriAgenics is in the pre-revenue stage and has completed pre-production prototype development. Leigh Colby founded TriAgenics in January 2013. The current crowdfunding campaign has a minimum target of $15,000 and a maximum target of $4 million. The campaign proceeds will be used for the FDA clearance application, conducting human clinical trials, company employment, operations, and consulting services.

Summary Profit and Loss Statement

FY 2022 FY 2021

Revenue

$0

$0

COGS

$859,420

$563,628

Tax

$3,442

$3,376

 

 

Net Income

$-1,433,220

$-1,062,543

Summary Balance Sheet

FY 2022 FY 2021

Cash

$1,458,412

$2,793,870

Accounts Receivable

$0

$0

Total Assets

$1,570,161

$2,980,140

Short-Term Debt

$49,913

$47,364

Long-Term Debt

$2,524

$4,476

Total Liabilities

$52,437

$51,840

Financials as of: 06/07/2023
Create a free account today to gain access to KingsCrowd analytics.

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.

Create your first portfolio

Create your own startup investment portfolio on KingsCrowd.

Track all of your startup investments in one place using our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
TriAgenics on StartEngine 2023
Platform: StartEngine
Security Type: Equity - Preferred
Valuation: $33,867,972
Price per Share: $3.00

Follow company

Follow TriAgenics on StartEngine 2023

Buy TriAgenics's Deal Report

TriAgenics Deal Report

Get KingsCrowd’s comprehensive report on TriAgenics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether TriAgenics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the TriAgenics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge